Business Wire

GLOBAL-BLUE

11.5.2021 14:10:07 CEST | Business Wire | Press release

Share
Brexit, an Opportunity Worth at Least €2.6 Billion for European Retailers

In its latest quarterly ‘Observatory’ report, Global Blue (NYSE:GB) has examined the potential impact of recent changes to Tax Free Shopping legislation in the UK on international shopper behaviour in Europe. The report includes findings of surveys amongst international shoppers1 and UK travellers2 .

With the gradual reopening of UK borders and their new eligibility to shop Tax Free in the EU, UK residents represent a new opportunity for European retailers

With the reopening of the UK borders planned after 17th May 2021, UK tourists are eager to return to travel and spending in Europe. 65% of them intend to travel abroad this year. Affluent tourists3 are the most likely to start travelling again soon, with 35% planning to travel during this summer’s holidays, versus 25% on average.

For summer 2021, their preferred destinations are influenced by sanitary conditions in relation to Covid-19, and are expected4 to be:

  • Spain (30%), + 12pt vs 2019
  • Greece (11%), + 7pt vs 2019
  • Italy (9%), + 4pt vs 2019
  • Portugal (9%), +5pt vs 2019
  • France (6%), -5pt vs 2019

However, preferred destinations are likely to evolve now that the UK Government’s ‘red, amber and green lists' are now official. Portugal is on the green list, while Spain, Greece, Italy and France remain on the amber one.

As of 1st January 2021, UK tourists are no longer considered as residents of the EU and are therefore now eligible for Tax Free Shopping in European stores. With British tourists taking around 70 million trips to Europe in 2019 and representing a total spend of around £40Bn, this market offers a strong opportunity for European retailers. British residents are expected to spend approximatively €1.1billion5 in sales-in-store in Europe per year once post-pandemic activity has fully resumed.

Currently, only 45% of those surveyed are already aware of Tax Free Shopping, with the remaining 55% needing to be informed of their new eligibility in European stores. Overall, 60% said they are more likely to spend in shops at destination if they can claim back the VAT. They are most likely to spend on clothes and accessories (70%), wine and alcohol (45%) and perfume and cosmetics (45%).

Continental European shopping destinations will attract more international shoppers following the abolition of the Tax Free Shopping scheme in the UK

A survey of 45,000 international shoppers by Global Blue showed that following the UK’s abolition of Tax Free Shopping on 1st January 2021, 90% of those who have shopped Tax Free in the UK over the last two years intend to choose an alternative destination for their next shopping trip, despite a large number of them still considering visiting the UK. Indeed, international shoppers visit 2.6 countries on average when coming to Europe and therefore have a choice of where to shop.

Overall, international shoppers are expected to reallocate at least €1.5billion of their shopping budget to alternative destinations: France is expected to attract the largest portion of these shoppers (40%), followed by Italy (30%), Germany (10%) and Spain (10%).

Mathieu Grac, VP Intelligence at Global Blue comment: “The new rules resulting from Brexit and the abolition of the Tax Free Shopping scheme in the UK have created a large opportunity for EU retailers to capture more business from international shoppers in the coming years. To realise this potential, it is important for the Europe’s retailers to understand the profiles of the new shoppers that will be coming into their stores and ensure that they can cater to their specific set of expectations.”

ABOUT GLOBAL BLUE

For more information: globalblue.com/corporate


1 Based on a survey at the end of 2020 of ~45,000 international shoppers who have shopped in the UK since Sept. 2018
2 Survey carried out in April 2021. 500+ answers collected from external panel of UK travellers and Global Blue’s database of UK shoppers
3 Affluent tourists are defined as those with a shopping budget of more than £1,000
4 Based on traveller assumption in April 2021
5 Global Blue and consulting firm estimates

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye